CM Hospitalar (VVEO3) Q2 2025 earnings summary

Executive summary

• Disciplined execution of strategic plans in 2024–2025 prioritized operational efficiency, commercial policy reviews, and integration efforts across business units.

• Emphasis shifted from quantity to quality, with gross margin and adjusted EBITDA margin expanding year-over-year due to pricing and contract selectivity strategies.

• Total sales grew 2.5% year-over-year in Q2 2025, driven by Laboratories, Vaccines, and Retail, offsetting declines in Hospitals and Clinics.

• Operational efficiency and working capital discipline led to a 12-day reduction in the cash cycle year-over-year.

• Significant investments included the launch of the largest wet wipes plant in Latin America and the acquisition of DF Log to enhance logistics.

Financial highlights

• Net revenue reached R$2,815.5 million in Q2 2025, up 2.5% year-over-year; 1H25 net revenue was R$5,600.4 million, down 1.7% year-over-year.

• Gross profit for Q2 2025 was R$422.5 million (+6.8% YoY), with a 15.0% margin.

• Adjusted EBITDA for Q2 2025 was R$177.9 million (+0.2% YoY), margin 6.3%.

• Free cash flow in Q2 2025 was R$176.8 million; cash cycle improved to 57 days from 69 days in Q2 2024.

• Adjusted net loss in Q2 2025 was R$44.3 million; leverage (Net Debt/Adjusted EBITDA LTM) at 4.44x (4.33x proforma including DF Log).

Outlook and guidance

• Growth expected in higher-margin, higher-ROIC businesses in H2 2025, with normalization of inventory and supplier profile anticipated.

• Focus remains on cash generation, deleveraging, and maintaining leverage below 3.5x by June 2027.

• Labs and vaccines expected to continue double-digit growth; services segment aims to resume growth through new customers and partnerships.

• Flat sales anticipated in H2, with some segments outpacing others.